Maxitrol®
neomycin 0.35%, polymyxin B, dexamethasone 0.1% · ophthalmic suspension
Antibiotic/Steroid
Approved uses
Steroid-responsive ocular inflammation where bacterial infection or a risk of infection exists
One to two drops in the conjunctival sac(s); in severe disease drops may be used hourly, tapered to discontinuation as the inflammation subsides, and in mild disease up to four to six times daily; not more than 20 mL should be prescribed initially
Controls post-cataract cells and flare as well as tobramycin-dexamethasone, with no 10 mmHg IOP rise.
Contraindications
- Most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella.
- Mycobacterial infection of the eye.
- Fungal disease of ocular structures.
- Known or suspected hypersensitivity to any ingredient of this preparation or to other corticosteroids.
Neomycin 3.5 mg/mL, polymyxin B sulfate 10,000 units/mL, dexamethasone 0.1% suspension, 5 mL in an 8 mL bottle.
Corticosteroid and anti-infective combination. Corticosteroids suppress the inflammatory response to a variety of agents and probably delay or slow healing. Because corticosteroids may inhibit the body's defense mechanism against infection, a concomitant antimicrobial may be used when this inhibition is considered clinically significant in a particular case. The anti-infective component is active against Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, and Pseudomonas aeruginosa.
Warnings & Precautions
- Cutaneous sensitization: Products containing neomycin sulfate may cause cutaneous sensitization, and sensitivity to topically administered aminoglycosides may occur in some patients; severity of hypersensitivity reactions may vary from local effects to generalized reactions such as erythema, itching, urticaria, skin rash, anaphylaxis, anaphylactoid reactions, or bullous reactions; discontinue treatment if hypersensitivity develops.
- Cross-hypersensitivity: Cross-hypersensitivity to other aminoglycosides can occur, and the possibility that patients who become sensitized to topical neomycin may also be sensitive to other topical and/or systemic aminoglycosides should be considered.
- Periocular contact allergy: In two German cohorts of patients with periorbital dermatitis, allergic contact dermatitis was the main cause (44.3% and 31.6%), and neomycin sulfate (8%) was among the most relevant allergens.
- Glaucoma and cataract: Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation.
- Host response suppression: Prolonged use may suppress the host immune response and thus increase the hazard of secondary ocular infections, and prolonged topical antibacterial use may give rise to overgrowth of non-susceptible organisms including fungi; suspect fungal invasion in any persistent corneal ulceration where a corticosteroid has been used or is in use, and culture when appropriate.
- Infection masking: Acute purulent or parasitic ocular infection may be masked or its activity enhanced by corticosteroid.
- Herpes simplex exacerbation: Ocular steroids may prolong the course and worsen many viral eye infections; treating a patient with a history of herpes simplex requires great caution, and frequent slit lamp microscopy is recommended.
- Corneal and scleral thinning: Various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal and scleral thinning, and use over thin corneal or scleral tissue may lead to perforation.
- Intraocular pressure: If used for 10 days or longer, IOP should be routinely monitored even though it may be difficult in children and uncooperative patients; use with caution in glaucoma and check IOP frequently.
- Delayed healing: The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.
- Not for injection: It should never be injected subconjunctivally or introduced directly into the anterior chamber of the eye.
- Coverage gap: No adequate coverage against Serratia marcescens or streptococci, including Streptococcus pneumoniae.
- Initial prescription and renewal: The initial prescription and renewal beyond 20 mL should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and where appropriate, fluorescein staining.
- Failure to improve: If signs and symptoms fail to improve after two days, the patient should be reevaluated.
- Persistent inflammation or pain: If inflammation or pain persists longer than 48 hours or becomes aggravated, the patient should discontinue use and consult a physician.
- Contamination: Avoid touching the bottle tip to eyelids or any other surface, and use of the bottle by more than one person may spread infection.
- Temporarily blurred vision: Vision may be temporarily blurred following dosing; care should be exercised in operating machinery or driving a motor vehicle.
Common Side Effects
Allergic sensitization is the reaction reported most often from the anti-infective component, and exact incidence figures are not available. Corticosteroid reactions include IOP elevation with possible glaucoma and infrequent optic nerve damage, posterior subcapsular cataract formation, and delayed wound healing, and corticosteroid-containing preparations have also been reported to cause perforation of the globe. Keratitis, conjunctivitis, corneal ulcers, and conjunctival hyperemia have occasionally been reported following use of steroids. Ulcerative keratitis, headache, and Stevens-Johnson syndrome have been identified from post marketing use. Cushing's syndrome and adrenal suppression may occur after dexamethasone use in excess of the listed dosing instructions in predisposed patients, including children and patients treated with CYP3A4 inhibitors.
Pregnancy: Dexamethasone is teratogenic in mice and rabbits after topical ophthalmic application in multiples of the therapeutic dose; in the mouse, corticosteroids produce fetal resorptions and cleft palate, and in the rabbit, fetal resorptions and multiple abnormalities involving the head, ears, limbs, palate, etc. There are no adequate or well-controlled studies in pregnant women, but prolonged or repeated corticoid use during pregnancy has been associated with an increased risk of intra-uterine growth retardation, and infants born of mothers who received substantial doses of corticosteroids during pregnancy should be observed carefully for signs of hypoadrenalism. Use in pregnancy only if the potential benefit to the mother justifies the potential risk to the embryo or fetus.
Lactation: Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when MAXITROL is administered to a nursing woman.
Safety and effectiveness below 2 years of age not established.